New Change to PEPFAR Will Slash CDC's Presence Abroad

- Former CDC director Tom Frieden has warned that upcoming changes to the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) will significantly reduce the CDC's presence in foreign countries.
- Frieden argues that slashing this international infrastructure leaves the U.S. more vulnerable to global health threats, citing current hantavirus and Ebola outbreaks as critical examples.
- This shift is significant because a diminished global footprint may hinder the ability to detect and manage emerging diseases before they reach domestic borders.
- The former director cautions that without robust overseas monitoring and infrastructure, the U.S. may be unprepared for a future outbreak that could be more severe than previous crises.
Sources & Citations
1 sourceMore Stories
Recent and anticipated novel drug approvals (1Q 2026 through 4Q 2026) | American Journal of Health-System Pharmacy
• The American Journal of Health-System Pharmacy has outlined the pharmaceutical pipeline for novel drug approvals anticipated between 1Q 2026 and 4Q 2026. • The upcoming pipeline focuses on therapies for rare inherited genetic disorders, immunologic and inflammatory diseases, and advancements in gene therapy and targeted oncology.
Read original · doi.orgTop Pharmaceutical Stocks To Watch Now – June 24th - Stock Observer
• MarketBeat’s stock screener tool identified Eli Lilly and Company, Pfizer, and Abbott Laboratories as the top pharmaceutical stocks to watch on June 24th. • These companies are highlighted for their roles in the research, development, manufacturing, and sale of medicines and healthcare products.
Read original · thestockobserver.comResearch Roundup - June 2026 - First10EM
• First10EM's June 2026 research roundup provides a critical appraisal of a recent emergency medicine trial regarding the use of whole blood. • The study yielded statistically negative results, but the data revealed a 5% increase in mortality among patients treated with whole blood.
Read original · first10em.com
First10EMOffice of Public Affairs | National Health Care Fraud Takedown Results in 455 Defendants Charged in Connection with Over $6.5 Billion in Alleged Fraud
• The U.S. Department of Justice announced the 2026 National Health Care Fraud Takedown, charging 455 defendants for their roles in massive fraud and opioid abuse schemes. • The group of defendants includes 90 doctors and other licensed medical professionals who allegedly submitted over $6.5 billion in false health care claims.
Read original · justice.gov
U.S. Department of JusticeTop news stories from AMA Morning Rounds®: Week of June 15, 2026
• The Centers for Medicare & Medicaid Services (CMS) has proposed a new rule to establish a permanent framework for its Medicare drug price negotiation program. • Scheduled to begin in 2029, the program focuses on negotiating and renegotiating prices for expensive, single-source drugs to reduce costs for millions of patients.
Read original · ama-assn.orgWhite House Policy Aide Reportedly In Running To Lead FDA - KFF Health News
• White House deputy assistant for domestic policy Heidi Overton is reportedly among the final candidates being considered to lead the Food and Drug Administration (FDA). • Overton is a medical doctor who holds a doctorate in clinical investigation from Johns Hopkins University, bringing significant medical and policy expertise to the role.
Read original · kffhealthnews.orgHHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials
• The U.S. Department of Health and Human Services (HHS) has launched a coordinated, department-wide initiative to restore American leadership in clinical research. • The ONC is working to integrate clinical trial notifications into electronic health records to connect eligible patients with research opportunities during routine care.
Read original · hhs.govInterpreting Epidemic Curves: The Big Picture
• The author challenges the public health establishment's claim that universal vaccination is the essential tool for preventing epidemics like Covid-19, polio, and measles. • The piece argues that while medical science is effective at a micro level, a macro-level analysis of epidemic curves is necessary to understand disease trajectories.
Read original · brownstone.org
Brownstone InstituteRecently Published
• The SODa-BIC Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group have published new research in The New England Journal of Medicine. • The study, identified by DOI:10.1056/NEJMoa2600526, focuses on clinical trials conducted within intensive care settings.
Read original · nejm.orgBIO 2026: US public health as we know it is gone. Can we rebuild a better system? - BioSpace
• Former leaders from the FDA, CDC, and NIH convened at the BIO International Convention to discuss the dismantling of the Department of Health and Human Services under the Trump administration. • The panel focused on the collapse of existing US public health structures and the urgent need to rebuild a more effective system.
Read original · biospace.com#75: Four medical breakthroughs that could change the next decade
• The author identifies four early-stage medical breakthroughs currently in clinical trials that could potentially treat major killers like cancer, heart disease, and neurodegenerative diseases. • While acknowledging that many promising medical ideas fail during development, these specific advances are being monitored with cautious optimism by leading research institutions.
Read original · timesofindia.indiatimes.comHealth Brief: FDA signals reset in drug reviews - The Washington Post
• The FDA has launched a new initiative aimed at resetting the drug review process to accelerate the development of new medications. • A primary goal of the program is to boost the number of domestic clinical trials, reducing reliance on overseas data and speeding up patient access to therapies.
Read original · washingtonpost.com
